Ethereum co-founder Vitalik Buterin challenged the idea that Ethereum's transaction fee-burning mechanism under EIP-1559 reliably supports ETH's valuation. He argued that ETH's value should focus more on its role as a store of value and the network's security, rather than on token scarcity from fee burning. Buterin noted that fee revenue depends heavily on market activity, which can be volatile, and emphasized preserving Ethereum's decentralization and censorship resistance over maximizing fee revenue. His comments suggest a shift toward valuing Ethereum's long-term network stability and security as key to ETH's worth, rather than relying on token destruction alone.
Ethereum co-founder Vitalik Buterin's comments on the fee-burning mechanism come as a backdrop to a broad market downturn among major cryptocurrencies. For readers following the crypto sector, here is Pluang's market snapshot as of Nov 09, 2026 02:21 WIB: out of 50 major cryptocurrencies, only 8 rose while 41 fell. Notable movers include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, ONE (Harmony) down 21.70% at Rp32 with a typical hold time of 153 days and a near-even Pluang order activity split, and BAL (Balancer) up 11.14% at Rp16,297 with a typical hold time of 85 days.
Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...
CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...
At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...
Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...
Bitcoin Cash (BCH) fell about 4.5% on November 8, extending its weekly losses beyond 13%, while Bitcoin remained stable near $75,800. BCH's price dropped below key support levels around $250 and tested $244, signaling weaker demand compared to Bitcoi...
